AU2022341942A1 - Pharmaceutical composition and use thereof - Google Patents
Pharmaceutical composition and use thereof Download PDFInfo
- Publication number
- AU2022341942A1 AU2022341942A1 AU2022341942A AU2022341942A AU2022341942A1 AU 2022341942 A1 AU2022341942 A1 AU 2022341942A1 AU 2022341942 A AU2022341942 A AU 2022341942A AU 2022341942 A AU2022341942 A AU 2022341942A AU 2022341942 A1 AU2022341942 A1 AU 2022341942A1
- Authority
- AU
- Australia
- Prior art keywords
- furmonertinib
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2021/117692 WO2023035223A1 (zh) | 2021-09-10 | 2021-09-10 | 药物组合物及其用途 |
| AUPCT/CN2021/117692 | 2021-09-10 | ||
| PCT/CN2022/086053 WO2023035611A1 (en) | 2021-09-10 | 2022-04-11 | Pharmaceutical composition and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022341942A1 true AU2022341942A1 (en) | 2024-05-02 |
Family
ID=85507161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022341942A Pending AU2022341942A1 (en) | 2021-09-10 | 2022-04-11 | Pharmaceutical composition and use thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240366600A1 (https=) |
| EP (1) | EP4398909A4 (https=) |
| JP (1) | JP2024533423A (https=) |
| KR (1) | KR20240074779A (https=) |
| CN (1) | CN117957000A (https=) |
| AU (1) | AU2022341942A1 (https=) |
| CA (1) | CA3231192A1 (https=) |
| IL (1) | IL311331A (https=) |
| MX (1) | MX2024002822A (https=) |
| WO (2) | WO2023035223A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116159062A (zh) * | 2021-11-24 | 2023-05-26 | 上海艾力斯医药科技股份有限公司 | 药物组合物及其用途 |
| JP2025510910A (ja) * | 2022-03-31 | 2025-04-15 | アストラゼネカ・アクチエボラーグ | 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤 |
| WO2024059962A1 (en) * | 2022-09-19 | 2024-03-28 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pharmaceutical composition and use thereof |
| CN116478138A (zh) * | 2023-04-21 | 2023-07-25 | 江苏艾力斯生物医药有限公司 | 一种甲磺酸伏美替尼原料药的结晶方法 |
| CN116893086A (zh) * | 2023-04-28 | 2023-10-17 | 江苏艾力斯生物医药有限公司 | 一种靶向药甲磺酸伏美替尼片的模拟片及其制备方法 |
| CN117547536A (zh) * | 2023-11-15 | 2024-02-13 | 江苏艾力斯生物医药有限公司 | 一种药物组合物、其制备方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105315259B (zh) * | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| CN107163026B (zh) * | 2016-03-07 | 2019-07-02 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 |
| CN110590749B (zh) * | 2016-03-07 | 2020-11-06 | 上海艾力斯医药科技股份有限公司 | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 |
-
2021
- 2021-09-10 WO PCT/CN2021/117692 patent/WO2023035223A1/zh not_active Ceased
-
2022
- 2022-04-11 CN CN202280061191.5A patent/CN117957000A/zh active Pending
- 2022-04-11 WO PCT/CN2022/086053 patent/WO2023035611A1/en not_active Ceased
- 2022-04-11 EP EP22866089.0A patent/EP4398909A4/en active Pending
- 2022-04-11 MX MX2024002822A patent/MX2024002822A/es unknown
- 2022-04-11 JP JP2024515562A patent/JP2024533423A/ja active Pending
- 2022-04-11 AU AU2022341942A patent/AU2022341942A1/en active Pending
- 2022-04-11 KR KR1020247011293A patent/KR20240074779A/ko active Pending
- 2022-04-11 US US18/690,221 patent/US20240366600A1/en active Pending
- 2022-04-11 IL IL311331A patent/IL311331A/en unknown
- 2022-04-11 CA CA3231192A patent/CA3231192A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117957000A (zh) | 2024-04-30 |
| KR20240074779A (ko) | 2024-05-28 |
| EP4398909A1 (en) | 2024-07-17 |
| CA3231192A1 (en) | 2023-03-16 |
| IL311331A (en) | 2024-05-01 |
| EP4398909A4 (en) | 2025-08-13 |
| WO2023035223A1 (zh) | 2023-03-16 |
| WO2023035611A1 (en) | 2023-03-16 |
| JP2024533423A (ja) | 2024-09-12 |
| US20240366600A1 (en) | 2024-11-07 |
| MX2024002822A (es) | 2024-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023035611A1 (en) | Pharmaceutical composition and use thereof | |
| CN113710658A (zh) | 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐 | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| WO2023093663A1 (en) | Pharmaceutical composition and use thereof | |
| US20220193066A1 (en) | Quinoline derivative used for combination treatment of small cell lung cancer | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| WO2024061203A1 (en) | Pharmaceutical composition and use thereof | |
| JP7571053B2 (ja) | 軟部肉腫の併用療法用キノリン誘導体 | |
| CN113116895A (zh) | 用于治疗神经母细胞瘤的喹啉衍生物 | |
| HK40110967A (zh) | 药物组合物及其用途 | |
| CN113750096A (zh) | 用于治疗外周t细胞淋巴瘤的喹啉衍生物 | |
| CN111821302A (zh) | 用于联合治疗软骨肉瘤的喹啉类化合物 | |
| HK40116696A (zh) | 药物组合物及其用途 | |
| WO2022171064A1 (zh) | 烟酰胺及含有其的组合物的制药用途 | |
| HK40065487A (en) | Quinoline derivative used for soft tissue sarcoma combination therapy | |
| CN112294814A (zh) | 用于治疗胶质母细胞瘤的喹啉衍生物 | |
| HK40067323A (en) | Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy |